Search

Your search keyword '"Drumel, Thomas"' showing total 13 results
Start Over Author "Drumel, Thomas"
13 results on '"Drumel, Thomas"'

2. Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Author

Gastinne, Thomas, primary, Le Bourgeois, Amandine, additional, Coste-Burel, Marianne, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Imbert, Berthe-Marie, additional, Drumel, Thomas, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Tessoulin, Benoit, additional, Jullien, Maxime, additional, Vantyghem, Sophie, additional, Bene, Marie C, additional, Moreau, Philippe, additional, Le Gouill, Steven, additional, and Chevallier, Patrice, additional

Published
2021
Full Text
View/download PDF

3. Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Author

Le Bourgeois, Amandine, primary, Coste-Burel, Marianne, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Imbert, Berthe-Marie, additional, Drumel, Thomas, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Tessoulin, Benoit, additional, Jullien, Maxime, additional, Vantyghem, Sophie, additional, Bene, Marie C, additional, Moreau, Philippe, additional, Le Gouill, Steven, additional, and Chevallier, Patrice, additional

Published
2021
Full Text
View/download PDF

4. Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

Author

Clemenceau, Beatrice, primary, Guillaume, Thierry, additional, Coste-Burel, Marianne, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Le Bourgeois, Amandine, additional, Imbert, Berthe-Marie, additional, Drumel, Thomas, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Tessoulin, Benoit, additional, Jullien, Maxime, additional, Vantyghem, Sophie, additional, Ollier, Jocelyn, additional, Bene, Marie C, additional, Moreau, Philippe, additional, Le Gouill, Steven, additional, Vie, Henri, additional, and Chevallier, Patrice, additional

Published
2021
Full Text
View/download PDF

5. Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Author

Jullien, Maxime, primary, Le Bourgeois, Amandine, additional, Coste-Burel, Marianne, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Audrain, Marie, additional, Rimbert, Marie, additional, Imbert, Berthe Marie, additional, Drumel, Thomas, additional, Le Gouill, Steven, additional, Moreau, Philippe, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Tessoulin, Benoit, additional, Vantyghem, Sophie, additional, Béné, Marie C, additional, Guillaume, Thierry, additional, and Chevallier, Patrice, additional

Published
2021
Full Text
View/download PDF

6. Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

Author

Le Bourgeois, Amandine, primary, Coste‐Burel, Marianne, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Imbert, Berthe‐Marie, additional, Drumel, Thomas, additional, Mahé, Beatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Tessoulin, Benoît, additional, Jullien, Maxime, additional, Vantyghem, Sophie, additional, Moreau, Philippe, additional, Le Gouill, Steven, additional, Béné, Marie C., additional, and Chevallier, Patrice, additional

Published
2021
Full Text
View/download PDF

8. Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

Author

Gastinne, Thomas, primary, Le Bourgeois, Amandine, additional, Coste‐Burel, Marianne, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Imbert, Berthe‐Marie, additional, Drumel, Thomas, additional, Mahe, Beatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Tessoulin, Benoit, additional, Jullien, Maxime, additional, Vanthygem, Sophie, additional, Béné, Marie C., additional, Moreau, Philippe, additional, Le Gouill, Steven, additional, and Chevallier, Patrice, additional

Published
2021
Full Text
View/download PDF

9. Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

Author

Chevallier, Patrice, primary, Coste‐Burel, Marianne, additional, Le Bourgeois, Amandine, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Béné, Marie C., additional, Imbert, Berthe‐Marie, additional, Drumel, Thomas, additional, Le Gouill, Steven, additional, Moreau, Philippe, additional, Mahe, Beatrice, additional, Dubruille, Viviane, additional, Blin, Nicolas, additional, Lok, Anne, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Jullien, Maxime, additional, Vanthygem, Sophie, additional, and Guillaume, Thierry, additional

Published
2021
Full Text
View/download PDF

10. Evaluation of the FilmArray® Pneumonia Plus Panel for Rapid Diagnosis of Hospital-Acquired Pneumonia in Intensive Care Unit Patients

Author

Crémet, Lise, primary, Gaborit, Benjamin, additional, Bouras, Marwan, additional, Drumel, Thomas, additional, Guillotin, Florian, additional, Poulain, Cécile, additional, Persyn, Elise, additional, Lakhal, Karim, additional, Rozec, Bertrand, additional, Vibet, Marie-Anne, additional, Roquilly, Antoine, additional, and Gibaud, Sophie, additional

Published
2020
Full Text
View/download PDF

11. Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant.

Author

Le Bourgeois, Amandine, Coste‐Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Imbert, Berthe‐Marie, Drumel, Thomas, Mahé, Beatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Gastinne, Thomas, Tessoulin, Benoît, Jullien, Maxime, Vantyghem, Sophie, Moreau, Philippe, Le Gouill, Steven, Béné, Marie C., and Chevallier, Patrice

Subjects
STEM cell transplantation, TRANSPLANTATION of organs, tissues, etc., MESSENGER RNA, COVID-19 vaccines, SARS-CoV-2, HEMATOPOIETIC stem cell transplantation, SARS-CoV-2 Delta variant
Abstract

Finally, the proportion of patients documented twice with the highest antibody level at SpV2 and SpV2+/SpV3 was similar between V3- and V3+ patients (50% vs. 60%, I P i = 0-55). Vaccine, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA, coronavirus disease 2019 (COVID-19), allogeneic haematopoietic stem cell transplantation, BNT162b2, third dose Keywords: coronavirus disease 2019 (COVID-19); vaccine; allogeneic haematopoietic stem cell transplantation; BNT162b2; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA; third dose EN coronavirus disease 2019 (COVID-19) vaccine allogeneic haematopoietic stem cell transplantation BNT162b2 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA third dose e38 e40 3 02/28/22 20220301 NES 220301 The efficacy of two doses of anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) messenger RNA (mRNA) vaccines, successfully demonstrated in healthy populations,1 is progressively reported in recipients of allogeneic haematopoietic stem cell transplant (allo-HSCT) with, surprisingly, high humoral antibody responses of ~80%.1-3 In our own experience based on an observational study of 117 allo-HSCT adult recipients, we found that 83% of them achieved a significant specific humoral response after two doses (V1 and V2) of BNT162b2 anti-SARS-CoV-2 mRNA vaccine (Pfizer BioNTech). [Extracted from the article]

Published
2022
Full Text
View/download PDF

12. Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy.

Author

Gastinne, Thomas, Le Bourgeois, Amandine, Coste‐Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Imbert, Berthe‐Marie, Drumel, Thomas, Mahe, Beatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Tessoulin, Benoit, Jullien, Maxime, Vanthygem, Sophie, Béné, Marie C., Moreau, Philippe, Le Gouill, Steven, and Chevallier, Patrice

Subjects
CHIMERIC antigen receptors, CHRONIC leukemia, ANTIBODY formation, COVID-19 vaccines
Abstract

All except two patients were in complete remission at the time of first vaccine, while three patients were still on therapy (revlimid I n i = 1, tafasitamab I n i = 1, chemotherapy I n i = 1). Keywords: COVID 19; vaccine; CAR-T cells; BNT162b2; SARS-CoV-2 mRNA EN COVID 19 vaccine CAR-T cells BNT162b2 SARS-CoV-2 mRNA 360 362 3 01/17/22 20220115 NES 220115 The efficacy of anti-SARS-CoV-2 messenger RNA vaccines was first demonstrated in healthy populations.1 It was later progressively reported in immunocompromised hosts, including patients with solid tumours,2 haematological malignancies, especially B-cell chronic lymphocytic leukaemia,3,4 as well as solid organ transplants.5,6 Surprisingly, the antibody response has been shown to be impressive (around 80%) only in recipients of allogeneic haematopoietic stem cells transplant.7-9 Another immunocompromised population is patients who have received chimeric antigen receptor-T (CAR T) cell therapy. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. [Extracted from the article]

Published
2022
Full Text
View/download PDF

13. Evaluation of the FilmArray ® Pneumonia Plus Panel for Rapid Diagnosis of Hospital-Acquired Pneumonia in Intensive Care Unit Patients.

Author

Crémet L, Gaborit B, Bouras M, Drumel T, Guillotin F, Poulain C, Persyn E, Lakhal K, Rozec B, Vibet MA, Roquilly A, and Gibaud S

Abstract

The FilmArray ® Pneumonia plus Panel (FAPP) is a new multiplex molecular test for hospital-acquired pneumonia (HAP), which can rapidly detect 18 bacteria, 9 viruses, and 7 resistance genes. We aimed to compare the diagnosis performance of FAPP with conventional testing in 100 intensive care unit (ICU) patients who required mechanical ventilation, with clinically suspected HAP. A total of 237 samples [76 bronchoalveolar lavages (BAL DS ) and 82 endotracheal aspirates (ETA DS ) obtained at HAP diagnosis, and 79 ETA obtained during follow-up (ETA TT )], were analyzed independently by routine microbiology testing and FAPP. 58 patients had paired BAL DS and ETA DS . The positivity thresholds of semi-quantified bacteria were 10 3 -10 4 CFUs/mL or 10 4 copies/mL for BAL, and 10 5 CFUs/mL or copies/mL for ETA. Respiratory commensals ( H. influenzae , S. aureus , E. coli , S. pneumoniae ) were the most common pathogens. Discordant results for bacterial identification were observed in 33/76 (43.4%) BAL DS and 36/82 (43.9%) ETA DS , and in most cases, FAPP identified one supplemental bacteria (23/33 BAL DS and 21/36 ETA DS ). An absence of growth, or polybacterial cultures, explained almost equally the majority of the non-detections in culture. No linear relationship was observed between bin and CFUs/mL variables. Concordant results between paired BAL DS and ETA DS were obtained in 46/58 (79.3%) patients with FAPP. One of the 17 resistance genes detected with FAPP ( mecA/C and MREJ) was not confirmed by conventional testing. Overall, FAPP enhanced the positivity rate of diagnostic testing, with increased recognition of coinfections. Implementing this strategy may allow clinicians to make more timely and informed decisions., (Copyright © 2020 Crémet, Gaborit, Bouras, Drumel, Guillotin, Poulain, Persyn, Lakhal, Rozec, Vibet, Roquilly and Gibaud.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results